Vlad Coric, Biohaven CEO
March 22, 2023 11:20 AM EDT
Deals

Bio­haven grabs TYK2/JAK1 drug for $20M to start, $950M on the line — to go af­ter Parkin­son's

Paul Schloesser

Associate Editor

Bio­haven is bet­ting big on tar­get­ing brain dis­or­ders such as Parkin­son’s and po­ten­tial­ly Alzheimer’s.

The Con­necti­cut biotech an­nounced Wednes­day that it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mod­er­na re­ports slow start to RSV sales as Ban­cel steps back from com­mer­cial role

Sarep­ta dis­con­tin­ues work on next-gen ex­on-skip­ping drug for Duchenne

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

Joe Jimenez's lat­est Adi­tum com­pa­ny lines up T cell en­gager from Chi­na

GSK CEO Em­ma Walm­s­ley on the new Trump ad­min­is­tra­tion, trust, AI and Chi­na

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times